Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Context The US Food and Drug Administration recently recommended that CYP2C19
genotyping be considered prior to prescribing clopidogrel, but the American Heart …

Background Previous studies have investigated the relationship between CYP2C19
polymorphism and clinical prognosis in coronary artery disease patients treated with …

Summary Background Cytochrome P450 2C19 (CYP2C19) is the principal enzyme
responsible for converting clopidogrel into its active metabolite, and common genetic …

The loss-of-function hepatic cytochrome P450 (CYP) 2C19* 2 allele has been associated
with reduced clopidogrel active metabolite generation and higher ex vivo platelet reactivity …

Background Clopidogrel requires transformation into an active metabolite by cytochrome P-
450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …

The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide
intersubject variability. To determine whether frequent functional variants of genes coding for …

Aims To perform a meta-analysis of the association between CYP2C19 loss-and gain-of-
function variants and cardiovascular outcomes and bleeding in patients with coronary artery …

Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated
with adverse clinical outcomes. CYP2C19 loss‐of‐function alleles play an important role in …

Loss-of-function (LOF) variants of cytochrome P450 2C19 (CYP2C19) have been
hypothesized to be associated with lesser degrees of platelet inhibition and increased risk …